Creatine and cyclocreatine attenuate MPTP neurotoxicity. - Wikidata - awgldk - TriplyDB

Creatine and cyclocreatine attenuate MPTP neurotoxicity.

Creatine and cyclocreatine attenuate MPTP neurotoxicity.

http://www.wikidata.org/entity/Q48223541

about

The promise of neuroprotective agents in Parkinson's disease Brain serotonin and dopamine modulators, perceptual responses and endurance performance during exercise in the heat following creatine supplementation Creatine for Parkinson's disease Creatine for Parkinson's disease The role of oxidative stress in Parkinson's disease Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives Nutraceuticals in Parkinson's Disease A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions Electron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial Bioenergetics Oxidative Stress in Neurodegenerative Diseases Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View Phosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effects Expression of creatine kinase isoenzyme genes during postnatal development of rat brain cerebellum: evidence for transcriptional regulation C. elegans S6K Mutants Require a Creatine-Kinase-like Effector for Lifespan Extension Comparative expression analysis of the phosphocreatine circuit in extant primates: Implications for human brain evolution Mitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifying A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.Creatine kinase B-driven energy transfer in the brain is important for habituation and spatial learning behaviour, mossy fibre field size and determination of seizure susceptibility.On the mechanisms of neuroprotection by creatine and phosphocreatine.Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine. Relevance to dopaminergic injury.Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.A potential role for creatine in drug abuse?Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.Irreversible brain creatine deficiency with elevated serum and urine creatine: a creatine transporter defect?Therapeutic use of creatine in brain or heart ischemia: available data and future perspectives.Targeting cellular energy production in neurological disorders.Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection.Animal models of Parkinson's disease.Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior.Antioxidants as treatment for neurodegenerative disorders.A review of creatine supplementation in age-related diseases: more than a supplement for athletes.Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone.Reactive oxygen species in skeletal muscle signaling.The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease.Synchrotron radiation Fourier-transform infrared and Raman microspectroscopy study showing an increased frequency of creatine inclusions in the rat hippocampal formation following pilocarpine-induced seizures D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease.Physiological phenotype and vulnerability in Parkinson's disease

P2860

Q21129436-1713DA3A-7069-4AFA-A3B5-4DB2325C8540 Q21245420-F688D5F9-0298-416F-A397-8BF75CBE37F3 Q24193947-A599087B-7A0C-4343-98C1-DD96BBDD5E1C Q24203799-240D1BFA-F81C-46F6-9F0C-7BED4BCA9F04 Q24307946-18D66F72-FA5D-442C-B64C-32C4FD9E5CD9 Q24631151-E3DC8DA6-64FF-436E-A8E4-105DBE2805E9 Q26747508-93BF9BF0-EC58-42CC-AC20-48E860EF5AB2 Q26752769-4D8EBBD3-7560-453E-B357-6F7B58A86EA7 Q26781560-208A32C7-3ECF-421D-A888-70588D4DC967 Q26795417-A63E34BB-4691-40E5-97B7-636DE6EE5596 Q26801239-15A38623-4E08-4B59-B745-AC5CAB017C67 Q28084254-0587A62B-79F9-40F0-A67F-9064B66E3245 Q28482353-D62DC8AD-1F91-4A40-8F6D-B87CA228C2D3 Q28579012-6E6E05F7-4420-4401-A2E0-931C0900748C Q28601083-E128A171-46F3-465C-8170-91DDE06AF0D1 Q28654485-298B7485-0F0E-4874-B0D3-EA954BC162F3 Q28732683-E2572222-46E8-4333-BF9B-66B7FB50A772 Q30407150-621591A5-CE5F-4784-92A0-8D6009AC2EBF Q30407589-A08CCAA6-EF27-404C-8DE3-52251E10482E Q30417007-78844DF7-508E-4FEE-988A-7B030B822FFB Q30697610-261C3BB4-C404-4753-9E13-4427063A053F Q32034781-4E6FD2BC-2233-40C3-ABBD-EF1D050B7279 Q33563284-6FA77B77-6614-42A4-AF91-74651BA201EF Q33837238-EFCAD6D7-6E65-4FC5-8F2B-68B196066E3B Q33844763-C2D78395-6D20-4AEC-9E5B-5C08E1D60582 Q33917550-157173FD-73E2-45B9-ACA3-316D22427691 Q33939183-8D924BD8-8873-48A6-8605-31C71302E953 Q34089086-DD94911F-393E-42D0-9151-5D62B42D1CCA Q34266266-065120F6-C2BE-4887-9ED1-38FF4B68228C Q34460675-1599A230-C656-475A-8A34-0CC2ED468227 Q34596189-FA68906F-B443-457A-B9E8-AA0EBB370131 Q34711201-9CCF33FA-9C1D-4454-9C93-C029533053D2 Q34974866-DCD0D0E2-07AA-4D64-83A1-D24CE04CFAAB Q35005568-EA6A5363-1229-49DF-9FDA-38A30B1EBA00 Q35045060-CC490387-251B-40D8-8009-D1353E5E4DE1 Q35607438-EB02DB07-1743-402F-A499-ECC0C704B28C Q35628604-76269EA0-0A39-48BC-A41F-16E3C01DB0BB Q35761665-AD45B0ED-9366-4426-9E63-0DA85CF26C19 Q35919815-CDFF9E33-8FF9-4EB9-AEAE-5F144B7583E1 Q36065850-C87BE0D6-D002-41CA-86D9-804DD9A4623C

P2860

Creatine and cyclocreatine attenuate MPTP neurotoxicity.

http://www.wikidata.org/entity/Q48223541

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

1999年學術文章

@zh-hant

name

Creatine and cyclocreatine attenuate MPTP neurotoxicity.

@en

Creatine and cyclocreatine attenuate MPTP neurotoxicity.

@nl

type

label

Creatine and cyclocreatine attenuate MPTP neurotoxicity.

@en

Creatine and cyclocreatine attenuate MPTP neurotoxicity.

@nl

prefLabel

Creatine and cyclocreatine attenuate MPTP neurotoxicity.

@en

Creatine and cyclocreatine attenuate MPTP neurotoxicity.

@nl

P1433

Q48223541-4C2F59DB-0355-4131-BB6E-8A617853FD85

P1476

Q48223541-1426E075-1821-437A-825C-0FE943B42249

P2093

Q48223541-0B402A61-1566-42A8-9689-263F1B1D3EEB

Q48223541-3815144C-2D40-483E-AA59-DC481FDB1924

Q48223541-3DF891FB-32BA-4190-92C8-0EEA5380906C

Q48223541-8DB18A06-9753-4F72-AF1C-B850B1FF45DA

Q48223541-B39A9CCD-CEB6-4614-9C3C-A6B99D059BD8

Q48223541-E14856DD-621F-4462-945A-FF971E493D7B

Q48223541-EE0BF257-E0DD-4FE9-9E9C-7A18A18F213C

Q48223541-F0B27BEA-E553-4F1F-A01B-58E5975AF76A

P304

Q48223541-F99F3FE1-E78C-43A5-9075-276A07F27504

P31

Q48223541-0C17FB62-2065-4AB6-B18D-2E9E434CEF02

P356

Q48223541-AD7B3389-3D1F-4882-A0AD-DA0CFD2B5F29

P407

Q48223541-10738DF5-CF57-4EDC-9CB4-1614FD476495

P433

Q48223541-F87BEB74-4AFA-4725-8173-4253E02A1D73

P478

Q48223541-33D1AC63-56D5-4F90-AEFE-A7E22DBCA048

P577

Q48223541-13E2858F-CD45-47B9-AFEE-903EA1BCD57E

P698

Q48223541-C396C72E-66F6-468E-92E7-FB62E04CDEB1

P921

Q48223541-435AF2AC-0683-4AF5-AC25-10A89F5474CE

P356

P1433

Experimental Neurology

P1476

Creatine and cyclocreatine attenuate MPTP neurotoxicity.

@en

P2093

Beal MF

http://www.w3.org/2001/XMLSchema#string

Ferrante RJ

http://www.w3.org/2001/XMLSchema#string

Kaddurah-Daouk R

http://www.w3.org/2001/XMLSchema#string

Klein AM

http://www.w3.org/2001/XMLSchema#string

Klivenyi P

http://www.w3.org/2001/XMLSchema#string

Matthews RT

http://www.w3.org/2001/XMLSchema#string

Mueller G

http://www.w3.org/2001/XMLSchema#string

Yang L

http://www.w3.org/2001/XMLSchema#string

P304

142-149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1006/EXNR.1999.7049

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

157

http://www.w3.org/2001/XMLSchema#string

P577

1999-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10222117

http://www.w3.org/2001/XMLSchema#string

P921